Nephrocare Health Services FY26 Revenue at ₹998.8 Cr, Up 32.2% YoY
Nephrocare Health Services reported a 32.2% YoY increase in FY26 revenue, reaching ₹998.8 crore. Adjusted EBITDA rose by 37.6% to ₹238.1 crore, and adjusted PAT increased by 74.6% to ₹128.3 crore. Q4 FY26 revenue grew by 21.2% YoY to ₹265.6 crore. The company served 36,981 guests and saw a 16.6% increase in treatments. International markets contributed significantly to revenue growth.
The robust financial results, including substantial revenue and profit growth, indicate a positive outlook for the company. The expansion into international markets and strategic initiatives contribute to a high potential impact.
The announcement highlights strong financial performance with significant increases in revenue, EBITDA, and PAT, along with growth in guest numbers and treatments.
Nephrocare Health Services Limited (NEPHROPLUS) has released its investor presentation regarding the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. The company's FY26 revenue stood at ₹998.8 crore, reflecting a 32.2% year-over-year increase. Adjusted EBITDA for FY26 was ₹238.1 crore, up by 37.6% YoY, and adjusted PAT reached ₹128.3 crore, a 74.6% increase YoY. The number of guests served increased to 36,981, and total treatments grew by 16.6% to 38,44,658.
For Q4 FY26, revenue was ₹265.6 crore, a 21.2% increase YoY, with adjusted EBITDA at ₹55.4 crore and adjusted PAT at ₹35.1 crore. Treatment volumes for the quarter increased by 15.2% YoY to 9,96,074. The company highlighted a favorable mix shift towards international markets, where revenue per treatment is higher, contributing to an uplift in overall revenue per treatment.
Management Commentary: Vikram Vuppala, Chairman and MD, noted that FY26 was an important year as the company transitioned into a publicly listed entity while delivering strong operating and financial performance. Rohit Singh, Group CEO, mentioned the focus remains on deepening the India presence, scaling international businesses, and evaluating opportunities in new geographies. Prashant Goenka, Group CFO, emphasized the balanced and disciplined growth approach, reflected in revenue, profitability, cash flows, and returns.
What to do with a filing like this
Nephrocare Health Services Limited filed this with the NSE as a statutory disclosure, categorised under investor presentation. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Nephrocare Health Services Limited. Read the original for the full detail.